N/A
N=10
Prone Breast Irradiation for Pendulous Breasts
Breast Cancer
Bottom Line
View on ClinicalTrials.gov: NCT00181363 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Jan 2020
Primary outcome: Primary: Dose Homogeneity 1: PTV — 9.8; 8.2; 48.2; 49.8 Gy — p=<0.05
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Mamma board (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Maastricht Radiation Oncology
- Primary completion
- Jul 2006
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Dose Homogeneity 1: PTV |
9.8; 8.2; 48.2; 49.8; 53.6; 54.8 | <0.05 sig |
| PRIMARY Dose Homogeneity 2: V105% and V107% |
1.5; 9.1; 0.1; 2.8 | <0.05 sig |
| PRIMARY Dose Homogeneity 3: V95 % |
78.6; 91.4; 85.0; 93.3 | <0.05 sig |
| SECONDARY PTV Coverage in Organs at Risk: MLD (Gy) |
0.9; 4.1 | <0.05 sig |
| SECONDARY PTV Coverage in Organs at Risk: Heart V30 |
2.4; 7.3 | <0.05 sig |
Summary
We hypothesize that for large pendulous breasts, breast irradiation in supine and prone position are equivalent with regard to coverage of the PTV, but with a better dose homogeneity in prone position and a smaller radiation exposure of lung and heart.The purpose of this study is to compare the 3-D dose distribution in PTV(Planning Target Volume) and normal tissues in prone position versus supine position.
Eligibility Criteria
Inclusion Criteria
- Patients should have had breast-conserving surgery for breast cancer or DCIS (Ductal Carcinoma in Situ)
- No indication for radiotherapy of regional nodes
- Large, pendulous breasts (bra size D and over)
Exclusion Criteria
- Regional radiotherapy is indicated
- Unable to lie in prone position
Data sourced from ClinicalTrials.gov (NCT00181363). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.